Evercore ISI initiated coverage of Augmedix with an In Line rating and $6 price target. The company, a leader in tech-enabled medical transcription services, stands to benefit from growing interest in large language models as hospitals look to further automate clinical workflow pain points such as documentation, the analyst tells investors in a research note. However, the firm sees multiple contraction to be just as, if not more, likely as multiple expansion, limiting room for upside in the stock.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AUGX:
- Augmedix Partners with Google Cloud to Bring Medically-Tuned AI Technology to Ambient Documentation
- Augmedix management to meet with Lake Street
- Augmedix Announces Closing of Public Offering of Common Stock, Including Additional Investments from HCA Healthcare and Redmile Group
- Augmedix 6.25M share Spot Secondary priced at $4.00
- Augmedix Announces Pricing of Upsized Public Offering of 6,250,000 Shares of Common Stock